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Abstract: Despite significant improvements in morbidity and mortality with current evidence-based
pharmaceutical-based treatment of heart failure (HF) over the previous decades, the burden
of HF remains high. An alternative approach is currently being developed, which targets
myocardial energy efficiency and the dysfunction of the cardiac mitochondria. Emerging evidence
suggests that the insufficient availability of ATP to the failing myocardium can be attributed to
abnormalities in the myocardial utilisation of its substrates rather than an overall lack of substrate
availability. Therefore, the development of potential metabolic therapeutics has commenced including
trimetazidine, ranolazine and perhexiline, as well as specific mitochondrial-targeting pharmaceuticals,
such as elamipretide. Large randomised controlled trials are required to confirm the role of
metabolic-modulating drugs in the treatment of heart failure, but early studies have been promising
in their possible efficacy for the management of heart failure in the future.
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1. Introduction
Despite advances in modern therapeutics and a significant reduction in mortality and morbidity,
the burden of heart failure (HF) remains significant [1]. It is estimated that there are 23 million people
with heart failure worldwide, with a lifetime risk for both men and women for developing heart failure
of one in five [1,2]. Heart failure causes around 5% of all adult hospital admissions [3], and in 2013, over
20% of deaths in the United States were determined to be attributed to heart failure [4]. HF mortality
remains high despite the establishment of renin-angiotensin-aldosterone blockade and beta-blockade as
mainstays of therapy [4]. Thus, emphasis on the development of alternative pharmacological strategies
is required [2]. Traditionally, the modification of hemodynamic and neurohormonal alterations that
occur in the failing heart have been the focus of treatment resulting in the use and development of
drugs aimed at improving hemodynamics, such as inotropes, beta-blockers and angiotensin-converting
enzyme (ACE) inhibitors [2,5]. However, with the failure of such therapies to improve heart failure
statistics, recent efforts have been directed instead towards utilisation of improved knowledge of
heart failure pathophysiology. This has led to recent interest in the development of therapeutics
aimed at enhancing myocardial energy efficiency via preferential metabolism of glucose as a substrate,
rather than fatty acids, in order to increase adenosine triphosphate (ATP) production per mole of
oxygen consumed [2,6–8]. Furthermore, with increasing evidence that the dysfunction of cardiac
mitochondria is pivotal in heart failure, the most recent medication developments have aimed to
improve mitochondrial functioning to maximise energy production [9–11]. This paper will seek to
define the metabolic and mitochondrial changes that occur in heart failure and explore the recent
advances in therapeutic options that target this metabolism.
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2. Metabolism in Heart Failure
The energy requirements of the myocardium are high and must be met in order to sustain cardiac
contraction [12]. The healthy human heart hydrolyses greater than 6 kg of ATP per day in support
of its normal functioning and workload [13]. Further, the capacity of myocardial ATP storage is
comparatively low [12] resulting in a high dependence on the ability of the heart to function to capacity
in relation to energy production. Aerobic cardiac ATP production is physiologically produced via
mitochondrial oxidation of carbohydrates and fatty acids [14]. Further ATP can be sourced via alternate
substrates, such as ketone bodies, in order to ensure the high energy requirements are met, referred
to as a high degree of metabolic flexibility [12]. In normal functioning, the majority (around 70%) of
cardiac ATP production is via fatty acid metabolism [3].
In patients with heart failure, the myocardium, despite being a metabolic omnivore in being able to
utilise various substrates, is unable to produce sufficient ATP to meet metabolic demands. Heart failure
is considered a condition of metabolic impairment due to the reduction in ATP production resulting in
energetic starvation [8]. Often insufficient energy supply to the myocardium appears to not be as a
result of a lack of substrate availability, but rather due to an abnormality in the myocardial utilisation
of these substrates [13]. The impairment in energy production is exacerbated by increasing metabolic
demands of the heart due to the excessive activation of the sympathetic nervous system known to
occur in patients with heart failure [13]. The modifications to metabolism and their mechanism are
complex, not fully understood and do differ among heart failure of different aetiologies, though there
is clear evidence that there are severe metabolic alterations in any failing heart [6].
The initial response to the failing myocardium is a downregulation of fatty acid metabolism with
a relative preservation or increase in glucose uptake [3]. There is a preferential glucose metabolism
due to a downregulation of pyruvate dehydrogenase (PDH) isoforms, which normally exert an
inhibitory effect on glucose oxidation [13]. Concurrently, there is a reduced expression of medium
chain acyl-CoA dehydrogenase of greater than 40% compared to normal [8]. Acyl-CoA is involved in
the process of fatty acid beta-oxidation, and with its downregulation, there is a net reduction in fatty
acid metabolism [13]. Fatty acid oxidation is also regulated, and reduced in heart failure, by peroxisome
proliferator-activated receptor (PPAR) nuclear receptors, which are important transcriptional regulators
of fatty acid oxidation [6].
As the pathological state of heart failure progresses, with the establishment of a compensatory
hyperadrenergic state, this initial response ultimately results in an elevated level of free fatty acids in
the serum [13]. An excess of circulating fatty acids, greater than the heart’s oxidative capacity, results in
the storage of free fatty acids as intramyocardial triglycerides. Such storage of triglycerides is associated
with both lipotoxicity and worsening of the established heart failure [15]. The excess of circulating
free fatty acids can also lead to the onset of insulin resistance [13]. Reduced insulin-dependent
glucose uptake follows cardiac insulin resistance [8], and an impairment of glucose metabolism
becomes evident as systolic dysfunction occurs in heart failure [6]. Further mechanisms of the changes
in carbohydrate metabolism in heart failure are not fully understood, and contradictory evidence
regarding cardiac glucose use exists [6]; though it is thought that the impaired oxidation of glucose
may be attributed to by any combination of ‘mitochondrial dysfunction, reduced expression of genes
involved in glycolysis and glucose oxidation or decreased abundance of the pyruvate dehydrogenase
complex’ [6], involved in glucose oxidation.
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Following insulin resistance and reduced glucose metabolism, the myocardium becomes
increasingly reliant on the metabolism of free fatty acids, and upregulation of this metabolism
occurs [15]. In comparison to glucose utilisation, free fatty acid oxidation requires a greater oxygen
requirement with decreased mechanical efficiency and ultimately a reduced ATP yield [13]. Thus,
fatty acid oxidation is considered to have an inferior energy efficiency, and following the shift toward
dependence on fatty acid metabolism, cardiac oxygen consumption increases by 30–50% [13].
Metabolism in Diabetic Cardiomyopathy
Diabetic cardiomyopathy, cardiac disease independent of vascular complications in diabetes, is
a heart failure syndrome worth considering due to its pathophysiology association with metabolic
abnormalities [16]. Early in diabetic cardiomyopathy, there is observable left ventricular hypertrophy
and myocardial remodelling, which progresses to cause abnormal left ventricular filling and diastolic
dysfunction followed by eventual systolic dysfunction [16]. Recent evidence suggests that alterations in
cardiac metabolism that occur in diabetes mellitus contribute towards this contractile dysfunction [17],
particularly due to the insulin resistance detected in the diabetic heart in numerous studies [18]. Similar
to other forms of heart failure, the major metabolic abnormalities occurring in diabetic cardiomyopathy
are elevations in fatty acid oxidation in the context of reduced glucose uptake and metabolism [16].
Diabetes mellitus results in alterations in carbohydrate metabolism, including impaired glucose
uptake and reduced glycolysis and pyruvate oxidation [17]. A reduction in GLUT4 protein, the
major cardiac glucose transporter, due to reduced transcription in diabetes [18], and impaired insulin
signaling in the diabetic heart result in the observable reduction in glucose uptake [17]. Additionally,
there is the promotion of reactive oxygen and nitrogen species by hyperglycemia, which leads to
myocardial apoptosis [17].
In contrast to glucose, fatty acid uptake across the plasma membrane is insulin independent,
allowing an augmentation of the delivery of circulating fatty acids to the myocytes for oxidation in
diabetes [17]. The fatty acid translocase/CD36, upregulated in the diabetic heart, is thought to be
important in the etiology of cardiac hypertrophy and diabetic cardiomyopathy [18]. There is also an
increased availability of fatty acids, within the circulation, given the enhanced lipolysis in adipose
tissue and higher lipoprotein synthesis in the liver in a diabetic patient [17]. Despite the advantage of
increased lipolysis in the setting of reduced glucose oxidation to ensure adequate ATP production,
eventually the fatty acid supply supersedes the oxidative capacity of the heart. Inevitably, excess fatty
acids are stored as triglycerides causing lipotoxicity, as discussed above, contributing to the initiation
and progression of cardiomyopathy [17]. Furthermore, as in heart disease, the oxidation of fat opposed
to glucose requires greater oxygen consumption, reducing cardiac efficiency and placing further strain
on the heart, potentiating disease progression [17].
A further factor influencing the development of heart disease in diabetics is the effect of
the forkhead box-containing protein of the subfamily 0 (Fox0). Fox0 proteins have recently been
identified as important targets of insulin and other growth factors, as they act in the myocardium [19].
Furthermore, Fox0 transcription factors have been identified to regulate cardiac growth, insulin
signaling and glucose metabolism in the heart [19]. Animal studies have suggested that Fox0 may
be persistently and pathologically activated in diabetes [20]. Excess activation of Fox0 is thought to
commence when the cardiac substrate use changes, outlined above, occur and with cardiomyocyte
insulin resistance [20]. The activation of Fox0 is considered likely to be significant in the metabolic
changes that underlie diabetic cardiomyopathy, but further studies to develop this prediction are
required [19].
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3. Metabolic Modulating Therapeutics
This improved understanding of the role of metabolism in the pathophysiology of heart failure
has prompted further research into potential metabolic therapies. The current European Society of
Cardiology (ESC) guidelines outline that the major aims of medical management of heart failure are the
alleviation of signs and symptoms, reduction in hospitalisations and decreased mortality [21]. Further,
improved quality of life and increased functional capacity are also emphasised as important objectives
of treatment, but are recognised as difficult to measure, limiting their use in clinical trials [21]. A number
of upcoming agents targeting metabolic modulation will be reviewed to determine effectiveness
regarding their ability to meet these objectives.
3.1. Trimetazidine
One metabolic modulator, which is already widely used in the treatment of stable angina pectoris
and has a relatively significant amount of evidence for use in the treatment of heart failure, is
trimetazidine [22]. Trimetazidine is administered orally in either immediate release 20-mg tablets,
three times daily, or via twice daily dosing of 35-mg modified-release tablets [23]. Trimetazidine is
an anti-ischemic agent, and the key known mechanism of action is via inhibition of the long-chain
mitochondrial 3-ketoacyl coenzyme A thiolase enzyme, resulting in the reduction of myocardial fatty
acid uptake and oxidation [23]. Partial inhibition of fatty acid oxidation enhances glucose oxidation,
a more efficient means of ATP production as discussed earlier [24]. Another potentially beneficial
mechanism of action is trimetazidine’s direct inhibition of cardiac fibrosis via reduction of collagen
accumulation and reduced connective tissue growth factor (CTGF) expression [25].
There is currently a lack of properly designed and controlled large clinical trials evaluating the
use of trimetazidine in heart failure, but a number of smaller studies and meta-analyses have been
performed with promising results [25], as summarised in Table 1. Further, trimetazidine has been
proven to have a high tolerability with an absence of adverse hemodynamic affects throughout its use
in acute coronary syndrome, suggesting that despite the relative absence of high quality evidence,
it could potentially be safely implemented in heart failure treatment in patients with angina based
on the current evidence alone [26]. Trimetazidine has been shown to have no effect on resting blood
pressure, while lowering resting heart rate by an average of just 2.6 beats per minute [22]. Therefore,
trimetazidine can be effective and safe in complementing standard therapies that do target these
hemodynamic parameters [23]. Moreover, trimetazidine has been shown to be increasingly effective, in
improving cardiac function and reducing symptoms of heart failure, when combined with metoprolol,
a class a beta 1–2 receptor blocker, than when treated with trimetazidine alone [27].
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Table 1. Summary of recent trials and previous meta-analyses investigating the use of trimetazidine in heart failure patients.
Study Year Study Design No. of Patients Patient Cohort Results
Li, Li [28] 2016 RCT with follow upperiod of 12 weeks 140
Patients with coronary
heart disease and heart
failure
Treatment with trimetazidine and metoprolol in addition to
conventional treatment compared to standard treatment alone
resulted in:
Greater improvement in BNP (t = 19.41 pg/mL, <0.01)
Improved LVEF (t = 1.683%, p < 0.05)
Grajek, Michalak [29] 2015 Meta-analysis of 3 RCTs 326
Patients with heart failure
of various aetiologies and
stages
Treatment with trimetazidine compared to placebo resulted in
a reduction of all-cause mortality (RR 0.283, p < 0.0001)
Zhou, Chen [30] 2014 Meta-analysis of 19 RCTs 1042
Patients with heart failure
of various aetiologies and
stages
Treatment with trimetazidine compared to conventional
treatment alone resulted in:
LVEF improvement (WMD 7.29%, p < 0.01)
Improved NYHA classification (WMD −0.55, 95% CI
−0.81–−0.28; p < 0.01)
No difference in exercise tolerance (WMD 18.58, p = 0.15)
No difference in all-cause mortality (RR 0.47; 95% CI 0.12–1.78;
p = 0.27)
Reduction in BNP (WMD −157.08 pg/mL; CI
−176.55–−137.62; p < 0.01)
Zhang et al. [22] 2012 Meta-analysis of 16 RCTs 884
Patients with heart failure
of various aetiologies and
stages
Treatment with trimetazidine compared to placebo resulted in:
No difference in all-cause mortality (RR 0.47, p = 0.27)
Improved LVEF (WMD 6.46%, p < 0.0001)
Reduced NYHA functional class (WMD −0.57, p = 0.0003)
Improved exercise tolerance (WMD 63.75 s, p < 0.0001)
Downregulation of BNP (WMD −203.4 pg/mL, p = 0.0002)
Fragasso et al. [31] 2012 Multi-centre retrospectivecohort study 669
Patients with
systolic-diastolic heart
failure with EF < 45% and
NYHA Class II–IV
Treatment with trimetazidine compared to conventional
treatment alone (after propensity score was performed)
resulted in:
Mortality risk reduction (HR 0.189; 95% CI 0.079–0.454;
p = 0.0002)
Reduction in CVD death (HR 0.072; 95% CI 0.019–0.286;
p = 0.0001) 10.4% reduction in hospitalization (p < 0.0005)
Gao et al. [32] 2011 Meta-analysis of 17randomised studies 955
Patients with heart failure
of various aetiologies and
stages
Treatment with trimetazidine compared to placebo resulted in:
Improved LVEF (WMD 7.49%, p < 0.01)
Reduced NHYA classification (WMD −0.41, p < 0.01)
Increased exercise tolerance (WMD 30.26 s, p < 0.01)
Reduced mortality (RR 0.29; 95% CI 0.17–0.49; p < 0.01)
Reduced cardiovascular events and hospitalisations (RR 0.42;
95% CI 0.30–0.58; p < 0.01)
RCTs = randomised control trials; BNP = brain natriuretic peptide; LVEF = left ventricular ejection fraction; RR = relative risk; WMD = weighted mean difference; NHYA = New York Heart
Association; CVD = cardiovascular.
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Trimetazidine has consistently been shown to be effective in improving the left ventricular ejection
fraction (LVEF), reducing the New York Heart Association (NYHA) classification, decreasing the rate
of hospitalisation and reducing the recorded brain natriuretic peptide (BNP) in patients with heart
failure [22,28,30,32]. A number of studies has also determined that trimetazidine is effective in reducing
all-cause mortality for patients with heart failure [29,31,32]. Zhang et al. [22] and Zhou and Chen [30]
contraindicated this result and concluded that there was no significant difference in all-cause mortality.
However, both studies considered that, given that cardiac cause of mortality was significantly reduced,
there remained a therapeutic benefit of treatment with trimetazidine. There is further contradictory
evidence regarding the statistical benefit of trimetazidine on exercise tolerance in heart failure. An
increased exercise tolerance time of at least 30 s with treatment with trimetazidine compared to placebo
has been reported [22,32]. Zhou and Chen [30] concluded that the difference in exercise tolerance was
not significantly different to that of conventional therapy, though did acknowledge the limitation of
the methodological quality of the included studies used in their meta-analysis.
3.2. Ranolazine
Ranolazine is a metabolic modulator, similar structurally to trimetazidine [7]. Ranolazine is a
partial fatty acid beta-oxidation inhibitor, when high serum concentrations are achieved, with reciprocal
increases in glucose oxidation and PDH activity [12]. However, the drug’s main mechanism of action
appears to be the inhibition of the late inward sodium channels [13]. The physiological inactivation
of this channel is disrupted in the failing myocyte leading to sodium-triggered calcium overload,
causing contractile and electrophysiological disturbances [13], which can increase left ventricular
diastolic tension and myocardial oxygen consumption [33]. Thus, in targeting the late sodium channel,
ranolazine reduces calcium overload in the myocyte, which hypothetically improves diastolic tension
and relaxation [34]. This action of ranolazine on the late inward sodium channels requires lower doses
than those required to provide the drug’s cardioprotective effect [12].
Ranolazine is currently approved for use in chronic angina, and there is some evidence suggesting
its clinical relevance in the treatment of heart failure [35], summarised in Table 2. The first clinical
study that specifically sought to determine the potential beneficial effects of ranolazine in heart failure
was in patients with preserved ejection fraction (Ranolazine for the treatment of Diastolic Heart Failure
(RALI-DHF) Proof-of-Concept Study) [34]. Maier et al. hypothesised that ranolazine would improve
diastolic dysfunction given its action in promoting calcium extrusion and following the success of
animal studies [34]. The study did demonstrate a reduction in left ventricular end-diastolic pressure
with ranolazine treatment compared to placebo, but could not determine if the small change in pressure,
2 mmHg, would have any clinical relevance [34]. Maier et al. also demonstrated an acute reduction of
systolic function following ranolazine administration, but it was concluded that this finding did not
preclude potential positive long-term effects [34]. Despite the small sample size of the RALI-DHF study,
the authors determined that ranolazine could provide improvement in the measure of hemodynamics,
but that there was no evidence of improvement in relaxation parameters [34].
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Table 2. Summary of clinical trials investigating the potential use of ranolazine in heart failure.
Study Year Study Design No. of Patients Patient Cohort Results
Murray, Colombo [36] 2014 Unblinded,non-randomised trial 109
Systolic or diastolic heart
failure patients with
NYHA Class II–IV
Treatment with ranolazine compared to standard heart failure
therapy alone resulted in:
Increased LVEF (>7 EFU, p < 0.001)
Cardiovascular event rate reduction
Maier et al. [34] 2013
Prospective, randomised,
double-blind,
placebo-controlled
proof-of-concept study
20
Patients with diastolic
heart failure with
preserved ejection fraction
(EF > 45%)
In comparison to placebo, treatment with ranolazine in heart
failure resulted in:
Reduced left ventricular end-diastolic pressure (2.2 mmHg,
p = 0.04)
Reduction in cardiac out (0.3 l/min) and stroke volume
(3.3 mL) (p = 0.04)
No difference in exercise tolerance
No difference in BNP levels
Morrow et al. [33] 2010
Randomised,
double-blind,
placebo-controlled trial
4543 Non-ST-segmentelevation ACS patients
Treatment with ranolazine compared to placebo resulted in:
13% reduction in the rate of recurrent ischemia (HR 0.87; 95%
CI 0.76–0.99; p = 0.03)
No difference in incidence of new or worsening heart failure
No difference in exercise performance
No change in BNP concentration
NYHA = Ney York Heart Association; LVEF = left ventricular ejection fraction; EFU = ejection fraction units; BNP = brain natriuretic peptide; ACS = acute coronary syndrome.
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More recently, Murray and Colombo investigated the benefit of ranolazine in both systolic and
diastolic dysfunction and found an improvement in the left ventricular ejection fraction in both classes
following ranolazine treatment [36]. Other benefits appeared to be a reduction in cardiovascular events,
fewer deaths and reduced hospitalisations. However, the study design was non-randomised and
underpowered, so only a potential benefit of ranolazine exists requiring further investigation. Further
evidence may be provided imminently as a further randomised control trial is currently underway
and has commenced enrolling patients. This trial, The Effects of Ranolazine on Exercise Capacity in
Patients with Heart Failure with Preserved Ejection Fraction (RAZE trial), is aimed at determining
the effect of ranolazine on exercise capacity in patients with heart failure with preserved ejection
fraction [37].
Despite the limited availability of clinical trial data supporting the use of ranolazine, several
experimental investigations indicate a benefit of ranolazine in the treatment of heart failure [38],
summarised in Table 3. Experiments on right ventricular muscle strips from end-stage human failing
hearts showed a clear and significant reduction in diastolic tension [39]. Canine studies have revealed
promising uses of ranolazine; diastolic benefits of restoration of myocyte relaxation, reduction in
resting tension and reduction in left ventricular end diastolic pressure have been observed [40,41].
Further, Rastogi et al. revealed improved ejection fraction and reduced end diastolic wall stress
following treatment with ranolazine with exaggeration of this benefit when ranolazine treatment was
combined with metoprolol or enalapril [42]. This evidence provides incentive for further research that
could demonstrate a clinical benefit of ranolazine in heart failure in the future.
Table 3. Non-clinical experiments examining the benefits of ranolazine in heart failure.
Study Year Study Design Results
Sossalla et al. [39] 2008
Treatment of myocytes of
10 isolated failing human
hearts with ranolazine
Treatment with ranolazine resulted in a reduction of
the diastolic tension (3.9 mN/mm2 reduction,
p < 0.05)
Rastogi et al. [42] 2008
Canine study of 28 dogs
with induced heart
failure with a
randomised, blinded,
placebo-controlled
design
Treatment with ranolazine alone in heart failure
resulted compared to placebo in:
Improved EF by 2% (p ≤ 0.05)
Reduction of EDWS by 14 gm/cm2
Treatment with combination of ranolazine and
enalapril compared to placebo resulted in:
Improved EF by 5% (p ≤ 0.05)
Reduction of EDWS by 13 gm/cm2
Treatment with combination of ranolazine and
metoprolol compared to placebo resulted in:
Improved EF by 7% (p ≤ 0.05)
Reduction of EDWS by 20 gm/cm2
Undrovinas et al. [40] 2006
Treatment of 26 isolated
canine hearts post
induction of heart failure
Ranolazine treatment of isolated canine hearts with
induced heart failure resulted in:
Restoration of normal myocyte relaxation
Reduction in the resting tension of the myocytes
Sabbah et al. [41] 2002
Canine study of 21 dogs
with induced heart
failure
Treatment of dogs with heart failure with ranolazine
resulted in:
Reduction of LVEDP by 3 mmHg (p = 0.001)
Increased cardiac output of 0.39 L/min (p = 0.01)
EF = ejection fraction; EDWS = end-diastolic circumferential wall stress; LVEDP = left ventricular
end-diastolic pressure.
3.3. Perhexiline
Perhexiline is another metabolically-acting drug that was originally developed as an anti-anginal
medication [43]. This drug was initially utilised in the 1970s; but the underlying mechanism was
not understood, and its use substantially declined due to identification of serious adverse effects,
including hepatotoxicity and neurotoxicity [7]. More recently, with improved understanding of the
drug’s pharmacokinetics, the toxicity has been found to be preventable with individualised dosing and
dosage titration to steady state levels between 150 and 600 mg/mL [7]. Perhexiline is now considered
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a relatively safe treatment for cardiac conditions, but remains difficult to use given the ongoing need
to individualise dosing and ongoing monitoring of plasma levels [44].
Perhexiline was first demonstrated to act in reducing fatty-acid oxidation in a 1995 experiment
monitoring the effect of perhexiline on rat hearts [45]. A reduction of fatty acid utilisation of 35% was
recorded with a concurrent increase in cardiac output of 80 mL/min/g (p < 0.05). This understanding
was extended by an additional rat study that identified perhexiline as an inhibitor of the enzyme
carnitine palmitoltransferase-1 (CPT-1), which was known to control access of long chain fatty acids to
the mitochondrial site of beta-oxidation [46]. Despite this improved understanding, it remains likely
that further pharmacological mechanisms remain undiscovered, and an additional four mechanisms of
the drug have since been reported with limited awareness of their influence on cardiovascular function,
limiting the clinical application of perhexiline [47].
The potential benefit of perhexiline in heart failure was observed in a later experiment that
recorded an improvement in rat heart diastolic function during ischemia [48]. However, this benefit was
not retained during reperfusion, and perhexiline had no impact on systolic function [48]. Perhexiline
is not yet available for use in heart failure, though a few small placebo-controlled clinical studies,
summarised in Table 4, suggest it may be effective in the future, and it is currently safely used in
treating chronic stable angina in Australia and parts of Asia [49].
Table 4. Summary of the clinical trials investigating the use of perhexiline in the management of
heart failure.
Study Year Study Design No. ofPatients Patient Cohort Results
Beadle et al.
[50] 2015
Randomised
double-blind
placebo-controlled
trial,
parallel-group
study
47
Patients with
systolic heart
failure of
non-ischemic
etiology with
NYHA class of
II–IV
Treatment of with perhexiline compared to
placebo in heart failure resulted in: 30%
increase in PCr/ATP ratio (p < 0.001) (no
change in placebo group) 52% of treated
patients improved by 1 NHYA class compared
to 20% improving in the placebo group
(p = 0.02)
No change in LVEF (p = 0.68)
No change in BNP levels
Abozguia et al.
[51] 2010
Randomised,
double-blind,
placebo-controlled,
parallel-group
trial
46
Patients with
symptomatic
exercise limitation
caused by
non-obstructive
hypertrophic
cardiomyopathy
Treatment of patients with hypertrophic
cardiomyopathy with perhexiline compared to
placebo resulted in:
Improved exercise capacity (VO2 increased by
2.1 mL/kg/min, p = 0.003)
Reportedly less symptoms (MLHFQ score
improved by 8, p < 0.001)
Improved NYHA classification in more
patients (67% of treated patients compared to
30% of control)
No significant difference in ejection fraction
Phan et al. [52] 2009 151
Patients with
chronic heart
failure (LVEF <
40% with NYHA
class > IIb) or
refractory angina
Treatment of patients with angina or heart
failure with perhexiline resulted in the majority
of patients reporting subjective symptom
reduction (58.9%)
Lee et al. [53] 2005
Randomised
double-blind
placebo-controlled
trial
56
Patient with
chronic heart
failure with EF <
40% and NYHA
Class II or III
already on optimal
treatment
Treatment of with perhexiline compared to
placebo in heart failure resulted in:
Increased VO2 max by 17% (p < 0.001) (no
change in placebo group)
Increased LVEF by 10% (p < 0.001) with no
change in the placebo group
Reduced symptoms of heart failure (MLHFQ
score reduced by 24%, p = 0.04) while placebo
group score was unchanged
Mean NYHA classification improved by 21%
(p = 0.02) with no change in the placebo group
PCr/ATP = phosphocreatine/adenosine triphosphate; NHYA = New York Heart Association; LVEF = left ventricular
ejection fraction; BNP = brain natriuretic peptide; VO2 max = peak exercise oxygen consumption; MLHFQ =
Minnesota Living with Heart Failure Questionnaire.
Diseases 2017, 5, 14 10 of 18
Lee et al. conducted an initial clinical trial to determine the efficacy of perhexiline in heart
failure, particularly its effect on the peak exercise oxygen consumption (VO2 max) [53]. Despite the
small sample size and short follow-up period of eight weeks, a clear improvement in peak oxygen
consumption was found following perhexiline treatment compared to no change in patients treated
with a placebo [53]. This improvement was larger than that which has been observed to occur via
treatment with ACE inhibitors and occurred in addition to optimal medical treatment [53]. Additional
findings included evidence that perhexiline improved left ejection fraction, symptoms, resting and
peak stress myocardial function and skeletal mass energetics [53]. Further clinical trials support a
subjective improvement in symptoms of heart failure in patients treated with perhexiline [50–52]. The
most recent available trial did produce contradictory evidence that there was no significant change
in left ventricular function or BNP following perhexiline treatment, but did conclude that treatment
improved cardiac energetics given the improvement in the phosphocreatine (PCr)/ATP ratio, a marker
of heart failure, which correlates with the New York Heart Association (NYHA) class [50]. This novel
evidence suggests that there may be a role of perhexiline in the metabolic modulation in heart failure
management; now, the drug can be utilised safely, but a further larger scale study is required to confirm
its use.
3.4. Etoximir
Etoximir is an inhibitor of CPT-1, similar to perhexiline. Initial animal studies of CPT-1 inhibition
suggested that etoximir also improved cardiac function in diabetic rats, and hence, human clinical
studies were performed [54]. Unfortunately, however, a randomized controlled trial etoximir vs.
placebo of 347 patients had to be terminated early due unacceptably high liver transaminase levels in
the etoximir group [55]. Following this study, due to safety concerns, etoximir was abandoned as a
potential therapeutic agent in HF.
3.5. Malonyl CoA Decarboxylase Inhibition
MCD inhibitors increase myocardial malonyl coenzyme A levels. This leads to inhibition of
CPT1, reducing fatty acid uptake and consequently increasing glucose metabolism similarly to
perhexiline [56]. MCD inhibitors have been shown to have some beneficial effects in small studies
in conditions, such as ischemia [57,58]; however, they have not yet been tested in the setting of
heart failure.
3.6. Dichloroacetate
Dichloroacetate (DCA) inhibits pyruvate dehydrogenase kinase, increasing mitochondrial
pyruvate dehydrogenase and thus increasing glucose oxidation and theoretically improving contractile
function. There is some evidence to suggest that DCA may be associated with improved left ventricular
function in animal studies [59]; however, older clinical trials in heart failure patients did not show any
significant benefit, and the issue has not been studied further since [60,61].
4. Mitochondrial Dysfunction
Further to the metabolic disturbances contributing to the development and progression of heart
failure, recent advances have emphasised the potentially key role of mitochondrial dysfunction in the
pathophysiology of heart failure. This role is not yet well understood, and some contradictory evidence
of the underlying mechanisms exists. However, it is likely that a combination of changes contribute
to mitochondrial errors that ultimately lead to heart failure and that increased understanding and
the adaptation of medications to target mitochondrial changes could be pivotal in advances in heart
failure treatment.
A potential mechanism under review is the disruption of mitochondrial biogenesis, the production
of new mitochondria, as an early event in the pathophysiology of heart failure [62]. Both human and
rat experiments have determined a reduction in mitochondrial DNA (mtDNA) copy number and
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mitochondrial content in the failing myocardium [9]. Moreover, the early reversal of this disruption
has been shown to be cardioprotective, suggesting a future target for therapy [62]. The generation of
new mitochondria is complex and is regulated and stimulated by peroxisome proliferator-activated
receptor gamma coactivator 1α (PCG1α), a nuclear-encoded protein, which is induced in states of
increased energy demand to activate mitochondrial proliferation [62]. It is possible that the reduction in
mitochondrial number observed in heart failure may be attributed to a diminution of PCG1α activity,
but contradictory study results have been reported [62]. Further studies with a focus on cardiac
hypertrophy have demonstrated that during early stages of compensated hypertrophy, mitochondrial
biogenesis signaling is preserved in order to ensure increased energy supply given the increased
cardiac workload [11]. In contrast, once decompensated heart failure becomes evident, a decline in
mitochondrial biogenesis signals, including PCG1α, is observed, illustrating this change as contributory
in the development of heart failure [11].
Overproduction of reactive oxygen species (ROS) has also been associated with the development
of structural and functional changes occurring in myocardial failure [9]. The oxidative stress that arises
in the setting of excess ROS has been causally linked to the progression of heart failure [63]. Many
intracellular ROS, including superoxide and hydroxyl radicals and hydrogen peroxide (H2O2), are
physiologically produced as a by-product of normal mitochondrial energy production. A variety of
factors contribute to the excess production of ROS that occurs in heart failure. Oxidative stress is known
to increase the activity of oxidase enzymes, which are partly responsible for increased levels of ROS [64].
A variety of studies have illustrated further contributory elements that lead to ROS accumulation in
heart failure of different aetiologies, including hyperglycemia, reduction of antioxidants and oxidative
injury following ischemia [65]. Moreover, once ROS excess develops, damage to cardiolipin, a key
mitochondrial membrane phospholipid required to support mitochondrial energy production, occurs,
stimulating a negative feedback with further ROS production and myocardial damage [14].
The role of ROS in the progression of heart failure is multifaceted and not fully understood.
Mitochondria and mtDNA are most susceptible to ROS damage given that the majority of ROS is
derived from the mitochondria and because the mitochondria lack histones, which are protective
against ROS [9]. Consequently, with mitochondrial ROS damage, there is impaired mitochondrial
functioning, including decreased transcription of mitochondrially-encoded subunits of the electron
transport chain and a reduced capacity for oxidative phosphorylation [66]. This mitochondrial
damage and dysfunction further aggravates the decreased energy metabolism observed in heart
failure and potentiates the metabolic changes previously outlined [9]. Following ROS impairment of
the mitochondria, cardiomyocyte function is inhibited in a myriad of ways, including in abnormalities
of contractility, ion transport and calcium cycling [67]. Additionally, ROS are known to regulate
signaling cascades, including protein kinase C (PKC), mitogen-activated protein kinase (MAPK), Jun
N-terminal kinase and Ras, all of which are implicated in hypertrophy [9].
An alternate pathway that is also likely to be related to the mitochondrial influence on heart
failure is changes in cardiolipin [14]. This role is closely related to that of ROS, as ROS are thought to
fuel the oxidation of cardiolipin, resulting in reduced fatty acid oxidation and propensity for myocyte
apoptosis [14]. Cardiolipin is important in the function of the ETC, as it binds cytochrome c, an
electron carrier, to the inner mitochondrial membrane, permitting efficient electron transfer between
complexes III and IV [68]. In the presence of ischemia, high calcium or high ROS, cardiolipin is
peroxidised, negating its function in binding cytochrome c and reducing the mitochondrial energy
production capacity [68]. A murine study has implicated a reduction of cardiolipin in the development
of mitochondrial respiratory dysfunction and metabolic stress and noted that a selective loss of
tetralinoleoyl cardiolipin, the predominant form in healthy mammalian hearts, occurs in heart failure
that does not occur as part of the normal aging process in the absence of cardiac pathology [69].
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5. Treatments Targeting Mitochondrial Dysfunction
In conjunction with metabolic modulation, recent efforts have focused on pursuing this
increasingly understood mitochondrial disturbance in the production of pharmaceuticals that seek
to rectify the underlying mechanisms. Further, it has also been revealed that the improved
myocardial function that occurs with the currently available therapies may be partly attributable
to the drugs’ effects on mitochondrial function [62]. For example, improved mitochondrial function
has been recorded following treatment with ACE inhibitors and angiotensin receptor II blockers,
medications proven to significantly improve survival when administered in heart failure [62].
Development of medications that specifically aim to influence the underlying mitochondrial deficits
has also commenced.
Elamipretide
Elamipretide, also referred to in the literature as Bendavia, Szeto–Schiller (SS)-31 or MTP-131,
was one of the first drugs developed to selectively target the mitochondrial ETC to optimize energy
efficiency [70]. Elamipretide is a Szeto–Schiller (SS) peptide; one of a family of compounds that
was recently discovered by chance to selectively target the ETC to improve the efficiency of electron
transport and restore cellular bioenergetics [70]. It is a water-soluble tetrapeptide composed of natural
and synthetic amino acids, which is capable of crossing cellular membranes [71]. Elamipretide has a
number of proposed mechanisms of actions. It is known to interact with the phospholipid cardiolipin,
which is exclusively present within the inner mitochondrial membrane [72]. The likely mechanism is
by the peptide binding to cardiolipin to prevent peroxidation by cytochrome c peroxidase, ensuring a
preservation of mitochondrial cristae integrity [73]. In binding to cardiolipin, elamipretide also ensures
close association of cardiolipin to cytochrome c, which is known to facilitate electron transport in the
ETC and maximize energy production efficiency [74]. Further, animal studies have suggested that
elamipretide restores the normal total levels of cardiolipin in the mitochondria when cardiolipin is
depleted in the pathologic state [71]. Elamipretide also assists in diminishing intracellular ROS levels
by reducing ROS production in the mitochondria in conjunction with acting to clear excess ROS [75].
For example, elamipretide treatment has been shown to reduce spontaneous generation of H2O2 in
isolated mitochondria [76]. Elamipretide exerts its function on mitochondria across all organ systems
and, so, has been investigated for use for a variety of diseases, including heart failure, ischemic heart
disease, acute kidney injury and metabolic disorders [70].
Despite a poverty of human clinical trials investigating the utilisation of elamipretide, a variety of
animal studies has provided evidence supporting its use in heart failure, summarised in Table 5. In
addition to outlining the mechanism of action of elamipretide, these animal studies have provided
promising results that the drug may be clinically useful. A number of studies noted an improvement
in left ventricular function in animals with induced heart failure treated with elamipretide [71,77].
Sabbah et al. demonstrated a significantly improved ejection fraction (Figure 1) in dogs with heart
failure treated with elamipretide for a three month period [71]. It is also shown to prevent adverse left
ventricular remodelling following ischemia, implicating a reduction in the development of heart failure
post infarction [72,77]. Further, via restoration of cardiac myosin binding protein-C, elamipretide may
contribute to improved left ventricular relaxation [78].
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Table 5. Experimental trials investigating the role of elamipretide in heart failure treatment.
Study Year Study Design No. of Patients Results
Daubert et al. [79] 2016
Phase I
randomised,
placebo-controlled
trial
36 patients with
stable heart failure
(EF < 45% and
NYHA Class II–III)
Heart failure treated with elamipretide compared to
placebo resulted in:
Reduced left ventricular end-systolic volume
(between-group difference −13.7; 95% CI −22.7–−4.8; p
= 0.005) and end-diastolic volume (between-group
difference −17.9 mL; 95% CI −30.6–−5.2; p = 0.009)
Elamipretide was well tolerated with no influence on
blood and pressure and heart rate
Sabbah et al. [71] 2016 Canine experiment 14 dogs
Treatment of dogs with heart failure with elamipretide
compared to intravenous saline resulted in:
Improved EF (6% increase compared to pretreatment, p
< 0.05) with no change in control
Reduced end-systolic LV volume (3 mL, p < 0.05)
compared to increased volume in the control group
Increased maximum rate of ATP synthesis and increased
ATP/ADP ratio (p < 0.05)
No effect on heart rate, mean aortic pressure, systemic
vascular resistance or LV end-diastolic volume
Gupta et al. [78] 2016 Canine experiment 14 dogs
Treatment of dogs with heart failure with elamipretide
resulted in restoration of near normal levels of
cMyBPC-S282 in the left ventricle (p < 0.05)
Shi et al. [72] 2015 Murine experiment 24 rats
Treatment of post-MI rats with elamipretide showed:
Restored gene expression of mitochondrial energy
metabolism
Promotion of mitochondrial biogenesis
Regulation of glucose and fatty acid oxidation related
gene expression
Preserved SERCA2a expression
Reduction in cardiac fibrosis
Dai et al. [77] 2014 Murine experiment 56 rats
Rats treated with elamipretide compared to water after
acute MI showed improved LV function and prevention
of adverse left ventricle remodelling.
Sabbah et al. [80] 2014 Canine experiment 12 dogs
Dogs with heart failure treated with elamipretide
compared to normal saline resulted in normalised
expression of cardiolipin-remodelling genes and
proteins (p < 0.05)
EF = ejection fraction; LV = left ventricle; cMyBPC-S282 = cardiac myosin binding protein-C at serine 282; SERCA2a
= sarco/endoplasmic reticulum; MI = myocardial infarct.
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Figure 1. Change Δ (treatment effect) effect between pretreatment and 12 weeks post-treatment for 
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and fractional area of shortening (FAS) in heart failure control dogs and heart failure dogs treated 
with elamipretide. Statistical significance based on t-statistics for two means. Bar graph depicted as 
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One human trial of use of elamipretide in humans is currently available. Daubert et al. aimed to 
ensure the safety of elamipretide treatment in patients with heart failure with reduced ejection 
fraction [79]. After administration of just a single dose, no subjects suffered any serious adverse 
events, and only one patient had to discontinue treatment due to non-serious adverse effects [79]. 
Further, the hemodynamic parameters of blood pressure and heart remained stable in all patients, 
suggesting that elamipretide may be tolerated in combination with current standard heart failure 
medications [79]. This trial, despite its small sample size, also resulted in a significant reduction in 
left ventricular volumes in patients treated with elamipretide compared to placebo [79]. Further, 
larger studies are required to fully investigate elamipretide to determine its safety in sequential 
dosing and its overall efficacy in heart failure, but it may be a useful therapeutic option for targeting 
mitochondrial dysfunction in the future. We are currently aware of one further randomised trial 
currently underway investigating the effect of multiple injections of elamipretide for patients with 
heart failure with reduced ejection fraction [81]. 
6. Conclusions 
Improved understanding of the detailed pathophysiology of heart failure has prompted 
investigations for future therapeutics. Heart failure is recognised as a state of myocyte energy 
starvation due to metabolic changes that inhibit optimal energy production [8,13]. Medications 
including trimetazidine, ranolazine and perhexiline are aimed at rectifying the metabolic 
abnormalities in the failing heart, and the results of initial trials have been promising in indicating 
their role in heart failure management. Furthermore, there is also improved knowledge around the 
pivotal role of mitochondrial dysfunction in contributing to this energy deprivation. Utilisation of 
this knowledge has only recently commenced, but elamipretide is likely to be the first of many 
medications targeting this area given the exciting improvements to left ventricular function it has 
made in initial investigations. Greater evidence, in the form of large randomised controlled trials, is 
required to confirm the role of elamipretide and metabolic-modulating drugs in the treatment of 
heart failure, but it is expected to be an area of great advances in the future. 
Figure 1. Change ∆ (treatment effect) effect betwee retreatment and 12 weeks post-treatment for
left ventricular (LV) end-diastolic volume (EDV), end-systolic volume (ESV), ejection fraction (EF) and
fractional area of shortening (FAS) in heart failure control dogs and heart failure dogs treated with
elamipretide. Statistical significance based on t-statistics for two means. Bar graph depicted as mean ±
SEM [71].
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One human trial of use of elamipretide in humans is currently available. Daubert et al. aimed
to ensure the safety of elamipretide treatment in patients with heart failure with reduced ejection
fraction [79]. After administration of just a single dose, no subjects suffered any serious adverse events,
and only one patient had to discontinue treatment due to non-serious adverse effects [79]. Further, the
hemodynamic parameters of blood pressure and heart remained stable in all patients, suggesting that
elamipretide may be tolerated in combination with current standard heart failure medications [79]. This
trial, despite its small sample size, also resulted in a significant reduction in left ventricular volumes
in patients treated with elamipretide compared to placebo [79]. Further, larger studies are required
to fully investigate elamipretide to determine its safety in sequential dosing and its overall efficacy
in heart failure, but it may be a useful therapeutic option for targeting mitochondrial dysfunction in
the future. We are currently aware of one further randomised trial currently underway investigating
the effect of multiple injections of elamipretide for patients with heart failure with reduced ejection
fraction [81].
6. Conclusions
Improved understanding of the detailed pathophysiology of heart failure has prompted
investigations for future therapeutics. Heart failure is recognised as a state of myocyte energy
starvation due to metabolic changes that inhibit optimal energy production [8,13]. Medications
including trimetazidine, ranolazine and perhexiline are aimed at rectifying the metabolic abnormalities
in the failing heart, and the results of initial trials have been promising in indicating their role in
heart failure management. Furthermore, there is also improved knowledge around the pivotal role of
mitochondrial dysfunction in contributing to this energy deprivation. Utilisation of this knowledge has
only recently commenced, but elamipretide is likely to be the first of many medications targeting this
area given the exciting improvements to left ventricular function it has made in initial investigations.
Greater evidence, in the form of large randomised controlled trials, is required to confirm the role of
elamipretide and metabolic-modulating drugs in the treatment of heart failure, but it is expected to be
an area of great advances in the future.
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